Orchestra BioMed Holdings (OBIO) Retained Earnings (2020 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Retained Earnings for 7 consecutive years, with -$383.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 1036045.95% year-over-year to -$383.3 million; the TTM figure through Mar 2026 stood at -$383.3 million (down 1036045.95% YoY), while the FY2025 annual figure was $416.1 million, up 21.38% from the prior year.
• Retained Earnings slipped to -$383.3 million in Q1 2026 per OBIO's latest filing, from $416.1 million in the prior quarter.
• Across five years, Retained Earnings topped out at $416.1 million in Q4 2025 and bottomed at -$383.3 million in Q1 2026.
• Historically, Retained Earnings has averaged $44.3 million across 5 years, with a median of -$10000.0 in 2023.
• Annual changes were most pronounced in 2024 — Retained Earnings surged 3427900.0% — and 2026, when it slumped 1036045.95%.
• Orchestra BioMed Holdings' Retained Earnings stood at -$8000.0 in 2022, then retreated by 25.0% to -$10000.0 in 2023, then soared by 3427900.0% to $342.8 million in 2024, then advanced by 21.38% to $416.1 million in 2025, then plunged by 192.12% to -$383.3 million in 2026.
• Business Quant data shows OBIO's Retained Earnings at -$383.3 million in Q1 2026, $416.1 million in Q4 2025, and $412.5 million in Q3 2025.